Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

Current treatment paradigms for lupus nephritis offer significant room for ... voclosporin and a drug in the calcineurin inhibitor class can lead to positive outcomes, she said that an end-of ...

No writing assistance was utilized in the production of this manuscript. Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus. Immunological features ...

Although the unpurified extract is reportedly an effective treatment for lupus nephritis in mice ... and tripdiolide (88.2%) groups than in the control group (35.7%). Serum levels of antibodies ...

Lupus nephritis (LN) has a strong prognostic impact in patients with SLE ... The PS-adjusted HR for CRR was 19 (95% CI 2.2 to 160.9). No patients with class V LN in the LCN group progressed to CKD, vs ...

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course ...

Objective Lupus nephritis (LN) is characterised by renal endothelial dysfunction ... All patients with LN flare had active, class IV nephritis by ISN/RPS criteria. Complement levels were lower (13±7 ...

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...

Starting in December 1999, patients with systemic lupus erythematosus, biopsy-proven lupus nephritis (class III-V ... serum creatinine >3.0 mg/dl (>265.2 µmol/l), and previous exposure to ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

(NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis ... ≤0.2 g/g (classified as ultra-low ...